Patent Grant
11944799
This description relates to generating an artificial pulse.
Ventricular assist devices, known as VADs, are types of blood pumps used for both short-term and long-term applications where a patient's heart is incapable of providing adequate circulation. For example, a patient suffering from heart failure may use a VAD while the patient awaits a heart transplant. In another example, a patient may use a VAD while the patient recovers from heart surgery. Thus, a VAD can supplement a weak heart or can effectively replace the natural heart's function. VADs can be implanted in the patient's body and powered by an electrical power source outside the patient's body.
In one general aspect, a continuous flow blood pump can be operated to provide pulsatile blood flow. The motor speed for the pump can be modulated in a repeating cycle that includes a sequence of two or more speed levels. Operation of the pump can produce pressure changes that imitate a rate of pressure change of a natural physiologic pulse.
In another general aspect, pumping blood in a pulsatile manner includes operating a blood pump at a first speed for a first period of time, reducing the speed of the blood pump from the first speed to a second speed, operating the blood pump at the second speed for a second period of time, reducing the speed of the blood pump from the second speed to a third speed, operating the blood pump at the third speed for a third period of time, and increasing the speed of the blood pump from the third speed to the first speed.
Implementations can include one or more of the following features. For example, increasing the speed of the blood pump from the third speed to the first speed includes increasing the speed of the blood pump from the third speed to a fourth speed, operating the blood pump at the fourth speed for a fourth period of time, and increasing the speed of the blood pump from the fourth speed to the first speed. The second period of time is longer than a sum of the first period of time and the third period of time. Operating the blood pump at the first speed, reducing the speed of the blood pump from the first speed to the second speed, operating the blood pump at the second speed, reducing the speed of the blood pump from the second speed to the third speed, operating the blood pump at the third speed, and increasing the speed of the blood pump from the third speed to the first speed comprise a cycle, and pumping blood in a pulsatile manner further includes repeating the cycle. The duration of the second period of time is greater than half of the duration of the cycle. Operating the blood pump at the second speed for the second period of time includes operating the blood pump to produce a blood flow rate that has a predetermined relationship relative to an average blood flow rate for the cycle. Operating the blood pump at the second speed for the second period of time includes operating the blood pump to produce a blood flow substantially the same as the average blood flow rate for the cycle.
One or more of reducing the speed of the blood pump from the first speed to a second speed, reducing the speed of the blood pump from the second speed to a third speed, and increasing the speed of the blood pump from the third speed to the first speed includes one or more of a step-wise reduction in speed and a curvilinear reduction in speed. Operating the blood pump at the second speed includes operating the blood pump at the second speed during at least a portion of a contraction of a ventricle of human heart that is in blood flow communication with the blood pump. Pumping blood in a pulsatile manner also includes determining, based on a relationship between a speed of the blood pump and a power consumption of the blood pump, a synchronization between operating the impeller at the second speed and contraction of a ventricle of a human heart that is in blood flow communication with the blood pump. A generated pulsatile blood flow includes a temporal rate of change of blood pressure that approximates a temporal rate of change of blood pressure of a physiologic pulse. One or more of reducing the speed of the blood pump from the first speed to a second speed, reducing the speed of the blood pump from the second speed to a third speed, and increasing the speed of the blood pump from the third speed to the first speed includes generating a drive signal at a first time to produce a corresponding change in operating speed at a desired time. The second period of time is greater than the first period of time.
In another general aspect, a blood pump controller includes a waveform generator to generate a waveform for operating a blood pump, and a drive waveform transmitter to supply the generated drive waveform to the blood pump. The generated waveform is configured to operate a blood pump at a first speed for a first period of time, reduce the speed of the blood pump from the first speed to a second speed, operate the blood pump at the second speed for a second period of time, reduce the speed of the blood pump from the second speed to a third speed, operate the blood pump at the third speed for a third period of time, and increase the speed of the blood pump from the third speed to the first speed.
Implementations can include one or more of the following features. For example, increasing the speed of the blood pump from the third speed to the first speed includes increasing the speed of the blood pump from the third speed to a fourth speed, operating the blood pump at the fourth speed for a fourth period of time, and increasing the speed of the blood pump from the fourth speed to the first speed. The second period of time is longer than a sum of the first period of time and the third period of time. Operating the blood pump at the first speed, reducing the speed of the blood pump from the first speed to the second speed, operating the blood pump at the second speed, reducing the speed of the blood pump from the second speed to the third speed, operating the blood pump at the third speed, and increasing the speed of the blood pump from the third speed to the first speed comprise a cycle, and wherein the generated waveform is configured to repeat the cycle. The duration of the second period of time is greater than half of the duration of the cycle. Operating the blood pump at the second speed for the second period of time includes operating the blood pump to produce a blood flow rate that has a predetermined relationship relative to an average blood flow rate for the cycle. Operating the blood pump at the second speed for the second period of time includes operating the blood pump to produce a blood flow substantially the same as the average blood flow rate for the cycle.
The generated waveform is configured to change the speed of the blood pump via one or more of a step-wise change in speed and a curvilinear change in speed. The generated waveform operates the blood pump at the second speed during a contraction of a ventricle of a human heart that is in blood flow communication with the blood pump. The blood pump controller further includes a processor configured to determine, based on a relationship between a speed of the blood pump and a power consumption of the blood pump, a synchronization between operating the blood pump at the second speed and a contraction of a ventricle of a human heart that is in blood flow communication with the blood pump. The generated waveform drives the blood pump to generate a temporal rate of change of blood pressure that approximates a temporal rate of change of blood pressure of a physiologic pulse. The generated waveform is further configured to produce a corresponding change in pump operating speed at a desired time. The second period of time is greater than the first period of time.
In another general aspect, producing a pulsatile blood flow having a relatively low pressure portion and a relatively high pressure portion and having a rate of pressure change that mimics a rate of pressure change of a natural physiologic pulse includes operating a continuous flow blood pump to produce a first blood flow rate through the continuous flow blood pump associated with the relatively low pressure portion of the pulsatile blood flow, operating the continuous flow blood pump to produce a second blood flow rate through the continuous flow blood pump associated with the relatively high pressure portion of the pulsatile blood flow, and controlling the continuous flow blood pump to increase a blood flow rate through the continuous flow blood pump from the first flow rate to the second flow rate to produce the rate of pressure change that mimics the rate of pressure change of the natural physiologic pulse.
Implementations can include one or more of the following features. For example, operating the continuous blood flow pump to produce the second blood flow rate can include operating the continuous blood flow pump at a first operating speed, and controlling can include operating the continuous blood flow pump at a second operating speed, the second operating speed being associated with a third blood flow rate, the third blood flow rate being greater than the second blood flow rate. Operating the continuous flow blood pump to produce the second blood flow rate includes operating the continuous flow blood pump to produce the second blood flow rate such that the relatively high pressure portion has a duration that is longer than a duration of the relatively low pressure portion. Repeating a cycle in which the duration of the relatively high pressure portion is greater than half of the duration of the cycle. The cycle includes operating the continuous flow blood pump to produce the first blood flow rate, operating the continuous flow blood pump to produce the second blood flow rate, and controlling the continuous flow blood pump to increase the blood flow rate. Operating the continuous flow blood pump to produce the second blood flow rate includes operating the continuous flow blood pump to produce the second blood flow rate such that the second blood flow rate has a predefined relationship with an average blood flow rate of the pulsatile blood flow. The second blood flow rate is substantially equal to an average blood flow rate of the pulsatile blood flow. Controlling the continuous flow blood pump to increase the blood flow rate includes controlling the continuous flow blood pump to increase the blood flow rate through the continuous flow blood pump from the first flow rate to the second flow rate such that the blood flow rate through the continuous flow blood pump overshoots the second flow rate to produce the rate of pressure change that mimics the rate of pressure change of the natural physiologic pulse.
The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features will be apparent from the description and drawings, and from the claims.
With reference to
The blood pump 100 includes a stator 120 and a rotor 140. The rotor 140 includes an impeller to move blood from the inlet cannula 112 to the outlet conduit 102. For example, the blood pump 100 can be the pump described in U.S. Provisional Patent Application Ser. No. 61/375,504, filed Aug. 20, 2010, the entire contents of which are hereby incorporated by reference. In some implementations, the rotor 140 is separated from an internal wall 115 of the housing 110 by a gap 108. In use, the gap is from approximately 0.1 millimeters to approximately 2.0 millimeters. For example, in some implementations, the gap 108 is approximately 0.5 millimeters during use. Additionally, in some implementations, the rotor has a weight from approximately 5 grams to approximately 50 grams. For example, in some implementations, the rotor 140 has a weight of approximately 10 grams.
The rotation speed of the rotor 140 can be controlled to produce a desired blood flow rate. The desired blood flow rate can be selected to provide a desired level of assistance to the patient's heart H. For example, the blood flow rate can be selected to partially assist the blood circulation function of the patient's heart H. Alternatively, the blood flow rate can be selected to substantially replace the blood circulation function of the patient's heart. The rate of flow of blood from the inlet cannula 112 to the outlet conduit 102 is controlled, at least in part, by controlling the rate of rotation of the rotor 140 based on a direct relationship between the pump speed and the rate of blood flow through the blood pump 100.
With reference to
Referring to
The puck-shaped housing 110 further includes a peripheral wall 116 that extends between the first face 111 and a removable cap 118. As illustrated, the peripheral wall 116 is formed as a hollow circular cylinder having a width W between opposing portions of the peripheral wall 116. The housing 110 also has a thickness T between the first face 111 and the second face 113 that is less than the width W. The thickness Tis from about 0.5 inches to about 1.5 inches, and the width W is from about 1 inch to about 4 inches. For example, the width W can be approximately 2 inches, and the thickness T can be approximately 1 inch.
The peripheral wall 116 encloses an internal compartment 117 that surrounds the dividing wall 115 and the blood flow conduit 103, with the stator 120 and the electronics 130 disposed in the internal compartment 117 about the dividing wall 115. The removable cap 118 includes the second face 113, the chamfered edge 114, and defines the outlet opening 105. The cap 118 can be threadably engaged with the peripheral wall 116 to seal the cap 118 in engagement with the peripheral wall 116. The cap 118 includes an inner surface 118a of the cap 118 that defines the volute 107 that is in fluid communication with the outlet opening 105.
Within the internal compartment 117, the electronics 130 are positioned adjacent to the first face 111 and the stator 120 is positioned adjacent to the electronics 130 on an opposite side of the electronics 130 from the first face 111. The electronics 130 include circuit boards 131 and various components 133 carried on the circuit boards 131 to control the operation of the pump 100 by controlling the electrical supply to the stator 120. The housing 110 is configured to receive the circuit boards 131 within the internal compartment 117 generally parallel to the first face 111 for efficient use of the space within the internal compartment 117. The circuit boards also extend radially-inward towards the dividing wall 115 and radially-outward towards the peripheral wall 116. For example, the internal compartment 117 is generally sized no larger than necessary to accommodate the circuit boards 131, and space for heat dissipation, material expansion, potting materials, and/or other elements used in installing the circuit boards 131. Thus, the external shape of the housing 110 proximate the first face 111 generally fits the shape of the circuits boards 131 closely to provide external dimensions that are not much greater than the dimensions of the circuit boards 131.
With continued reference to
Each of the pole piece 123a-123f is L-shaped and has a drive coil 125 for generating an electromagnetic field to rotate the rotor 140. For example, the pole piece 123a has a first leg 124a that contacts the back iron 121 and extends from the back iron 121 towards the second face 113. The pole piece 123a also has a second leg 124b that extends from the first leg 124a towards the dividing wall 115 proximate the location of the permanent magnet 141 of the rotor 140. Each of the pole pieces 123a-123f also has a levitation coil 127 for generating an electromagnetic field to control the radial position of the rotor 140.
Each of the drive coils 125 and the levitation coils 127 includes multiple windings of a conductor around the pole pieces 123a-123f. Particularly, each of the drive coils 125 is wound around two adjacent ones of the pole pieces 123, such as pole pieces 123d and 123e, and each levitation coil 127 is wound around a single pole piece. The drive coils 125 and the levitation coils 127 are wound around the first legs of the pole pieces 123, and magnetic flux generated by passing electrical current though the coils 125 and 127 during use is conducted through the first legs and the second legs of the pole pieces 123 and the back iron 121. The drive coils 125 and the levitation coils 127 of the stator 120 are arranged in opposing pairs and are controlled to drive the rotor and to radially levitate the rotor 140 by generating electromagnetic fields that interact with the permanent magnetic poles S and N of the permanent magnet 141. Because the stator 120 includes both the drive coils 125 and the levitation coils 127, only a single stator is needed to levitate the rotor 140 using only passive and active magnetic forces. The permanent magnet 141 in this configuration has only one magnetic moment and is formed from a monolithic permanent magnetic body 141. For example, the stator 120 can be controlled as discussed in U.S. Pat. No. 6,351,048, the entire contents of which are incorporated herein by reference. The control electronics 130 and the stator 120 receive electrical power from a remote power supply via a cable 119 (
The rotor 140 is arranged within the housing 110 such that its permanent magnet 141 is located upstream of impeller blades in a location closer to the inlet opening 100. The permanent magnet 141 is received within the blood flow conduit 103 proximate the second legs 124b of the pole pieces 123 to provide the passive axial centering force though interaction of the permanent magnet 141 and ferromagnetic material of the pole pieces 123. The permanent magnet 141 of the rotor 140 and the dividing wall 115 form a gap 108 between the permanent magnet 141 and the dividing wall 115 when the rotor 140 is centered within the dividing wall 115. The gap 108 may be from about 0.2 millimeters to about 2 millimeters. For example, the gap 108 is approximately 1 millimeter. The north permanent magnetic pole N and the south permanent magnetic pole S of the permanent magnet 141 provide a permanent magnetic attractive force between the rotor 140 and the stator 120 that acts as a passive axial centering force that tends to maintain the rotor 140 generally centered within the stator 120 and tends to resist the rotor 140 from moving towards the first face 111 or towards the second face 113. When the gap 108 is smaller, the magnetic attractive force between the permanent magnet 141 and the stator 120 is greater, and the gap 108 is sized to allow the permanent magnet 141 to provide the passive magnetic axial centering force having a magnitude that is adequate to limit the rotor 140 from contacting the dividing wall 115 or the inner surface 118a of the cap 118. The rotor 140 also includes a shroud 145 that covers the ends of the impeller blades 143 facing the second face 113 that assists in directing blood flow into the volute 107. The shroud 145 and the inner surface 118a of the cap 118 form a gap 109 between the shroud 145 and the inner surface 118a when the rotor 140 is levitated by the stator 120. The gap 109 is from about 0.2 millimeters to about 2 millimeters. For example, the gap 109 is approximately 1 millimeter.
As blood flows through the blood flow conduit 103, blood flows through a central aperture 141a formed through the permanent magnet 141. Blood also flows through the gap 108 between the rotor 140 and the dividing wall 115 and through the gap 109 between the shroud 145 and the inner surface 108a of the cap 118. The gaps 108 and 109 are large enough to allow adequate blood flow to limit clot formation that may occur if the blood is allowed to become stagnant. The gaps 108 and 109 are also large enough to limit pressure forces on the blood cells such that the blood is not damaged when flowing through the pump 100. As a result of the size of the gaps 108 and 109 limiting pressure forces on the blood cells, the gaps 108 and 109 are too large to provide a meaningful hydrodynamic suspension effect. That is to say, the blood does not act as a bearing within the gaps 108 and 109, and the rotor is only magnetically-levitated.
Because the rotor 140 is radially suspended by active control of the levitation coils 127 as discussed above, and because the rotor 140 is axially suspended by passive interaction of the permanent magnet 141 and the stator 120, no rotor levitation components are needed proximate the second face 113. The incorporation of all the components for rotor levitation in the stator 120 (i.e., the levitation coils 127 and the pole pieces 123) allows the cap 118 to be contoured to the shape of the impeller blades 141 and the volute 107. Additionally, incorporation of all the rotor levitation components in the stator 120 eliminates the need for electrical connectors extending from the compartment 117 to the cap 118, which allows the cap to be easily installed and/or removed and eliminates potential sources of pump failure.
In use, the drive coils 125 of the stator 120 generates electromagnetic fields through the pole pieces 123 that selectively attract and repel the magnetic north pole N and the magnetic south pole S of the rotor 140 to cause the rotor 140 to rotate within stator 120. As the rotor 140 rotates, the impeller blades 143 force blood into the volute 107 such that blood is forced out of the outlet opening 105. Additionally, the rotor draws blood into pump 100 through the inlet opening 101. As blood is drawn into the blood pump by rotation of the impeller blades 143 of the rotor 140, the blood flows through the inlet opening 101 and flows through the control electronics 130 and the stator 120 toward the rotor 140. Blood flows through the aperture 141a of the permanent magnet 141 and between the impeller blades 143, the shroud 145, and the permanent magnet 141, and into the volute 107. Blood also flows around the rotor 140, through the gap 108 and through the gap 109 between the shroud 145 and the inner surface 118a of the cap 118. The blood exits the volute 107 through the outlet opening 105.
A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the claimed invention. For example, the cap 118 can be engaged with the peripheral wall 116 using a different attachment mechanism or technique, including snap-fit engagement, adhesives, or welding. Additionally, while the cap 118 has been described as defining the outlet opening 105 and the chamfered edge 114, the outlet opening 105 and/or the chamfered edge 114 can be defined by the peripheral wall 116 or by both the peripheral wall 116 and the cap 118. Similarly, the dividing wall 115 can be formed as part of the cap 118.
Additionally, the rotor 140 can include two or more permanent magnets. The number and configuration of the pole pieces 123 can also be varied. The operation of the control electronics 130 is selected to account for the number and position of pole pieces of the stator and permanent magnets of the rotor. Also, the cap 118 can be engaged with the peripheral wall using other techniques, such as adhesives, welding, snap-fit, shrink-fit, or other technique or structure. Similarly, the first face 111 may be formed from a separate piece of material than the peripheral wall 116 and the first face 111, including the inlet cannula 112, can be attached to the peripheral wall 116, such as by welding, after the control electronics 130 and the stator 120 have been mounted in the internal compartment 117. The shroud 145 may be omitted and optionally replaced by other flow control devices to achieve a desired pump efficiency. As another option, the control electronics 130 can be located external to the pump 100, such as in a separate housing implanted in the patient's abdomen, or external to the patient's body.
In some implementations, the dimensions of the housing 110 can be larger or smaller than those described above. Similarly, the ratio of the width W of the housing 110 to the thickness T of the housing can be different than the ratio described above. For example, the width W can be from about 1.1 to about 5 times greater than the thickness T. Additionally, the permanent magnet 141 of the rotor 140 can include two or more pairs of north and south magnetic poles. While the peripheral wall 116 and the dividing wall 115 are illustrated as cylinders having circular cross-sectional shapes, one or both can alternatively be formed having other cross-sectional shapes, such as oval, or an irregular shape. Similarly, the peripheral wall 116 can be tapered such that the housing does not have a constant width W from the first face 111 to the second face 113.
As mentioned above, in some implementations, the blood pump 100 can be used to assist a patient's heart during a transition period, such as during a recovery from illness and/or surgery or other treatment. In other implementations, the blood pump 100 can be used to partially or completely replace the function of the patient's heart on a generally permanent basis, such as where the patient's aortic valve is surgically sealed.
In addition to producing blood flow at a desired rate, a pulsatile blood flow pattern may be desired. A pulsatile blood flow pattern includes time periods of relatively high blood flow rates and blood pressures and time periods of relatively low blood flow rates and blood pressures. Such a pulsatile blood flow pattern may be desired to augment or replace a weakened pulse in patients, especially those whose native cardiac output is small compared to the volume flow rate of the blood pump. Additionally, a pulsatile blood flow pattern may be desired to produce a physiologic response similar to that of a native pulsatile blood flow pattern and/or blood pulse pressure from a healthy heart. This physiologic response may be markedly different than the response of a blood pump operating at a constant speed. While non-pulsatile circulation can lead to certain physiologic, metabolic, and vasomotor changes, the clinical relevance of pulsatility for VADs is unclear. Nevertheless, it is hypothesized that pulsatile circulation may reduce blood stasis in the ventricles, help exercise the aortic valve, improve washing on the distal side of atherosclerotic lesions, increase coronary and/or end organ perfusion, reduce the risk of ventricular suction, reduce the propensity for maladies related to reduced pulsatility, such as arteriovenous malformations, and increase myocardial recovery. Further, it is expected that these phenomena do not require mimicking a native pulse waveform in its entirety. Rather, such may be accomplished with the techniques and waveforms described herein.
Importantly, various characteristics of the artificial pulse may differ substantially from those of a physiologic pulse even while producing a response in the body that is similar to that caused by the physiologic pulse. Although with the multitude of potential clinical advantages there may be different aspects of a native pulse that mediate physiologic response, it is generally understood that the dominant source of dissipated energy that characterizes a meaningful pulse is the pressure wave generated at the start of cardiac systole. Accordingly, the artificial pulse described herein can include a relatively brief perturbation of a nature designed to produce such dissipated energy.
In some implementations, an artificial pulse cycle includes a perturbation period that simulates the pulse pressure that occurs at the leading edge of systole of a physiologic pulse. The perturbation period can include, for example, a period during which the blood pump 100 is operated at a low speed, followed immediately by a period during which the blood pump 100 is operated at a higher speed. The artificial pulse cycle can also include a period longer than the perturbation period during which the pump 100 is operated at an intermediate speed, for example, a speed maintained between the speeds realized during the perturbation period.
Operating the pump at the intermediate speed can contribute to a high operating efficiency. The efficiency achieved can be greater than, for example, the efficiency of a pump that only alternates between equal periods of operation at a high speed and at a low speed. Typically, a continuous flow pump operates with highest efficiency near the middle of its rotational speed range. Therefore, it can be advantageous to operate such a pump at or near a mid-range speed for at least a portion of an artificial pulse cycle.
Some of the parameters that affect physiologic phenomena include pulse pressure and the rate of blood pressure change (dp/dt). For the blood pump 100, for example, pulse pressure and time variation in blood pressure are affected by the angular velocity of the rotor 140. Thus, the blood pump 100 can be selectively controlled to produce a pulsatile blood flow pattern, including a desired pulse pressure and/or a desired rate of pressure change, by producing a pump speed pattern that includes a time period of relatively high rotor rotation speeds and a time period of relatively low rotor rotation speeds. In some implementations, the pulse pressure produced by the blood pump 100 or produced by the blood pump 100 and the patient's heart H in combination can be approximately 10 mmHg or more, such as from approximately 20 mmHg to approximately 40 mmHg.
For example, the blood pump 100 can be operated to produce a pump speed pattern 200, illustrated in
The first portion 210 and/or the second portion 220 of the pump speed pattern 200 can include multiple segments. In some implementations, the segments each have predetermined durations. As also shown in
In the pump speed pattern 200, the second rotation speed ω2 is a target high blood flow pump speed, and the first rotation speed ω1 is a desired overshoot pump speed that is selected to increase the rate of change of the blood pressure during the first period. The first period of time from the time T0 to the time T1, during which the blood pump 100 is operated at the first rotation speed ω1, is shorter than the second period of time from the time T1 to the time T2, during which the blood pump 100 is operated at the second rotation speed ω2. The first period of time can be from approximately 0.01 seconds to approximately 1 second. In some implementations, the first period of time is approximately 0.05 seconds in duration. In some implementations, the first period of time can be approximately equal to, or greater than the second period of time.
Additionally, the duration of the first period can be selected to produce a desired pulse pressure, i.e., the difference between blood pressure before the speed change time T1 and during the time T1, and can be selected independently of the duration of the second period of time. The first portion 210, including the first and second time periods from the time T0 to the time T2, is longer than the second portion 220. In some implementations, the first and second time periods from the time T0 to the time T2 can be shorter than, longer than, or substantially the same duration as the second portion 220. For example, to increase the duration of pumping at the higher flow rate relative to pumping at the lower rate while still benefiting from the occasional pulse, it may be advantageous for the first portion 210 to be longer than the second portion 220. If desired, the speed of the blood pump 100 is increased to the first rotation speed ω1 and the pump speed pattern 200 can be repeated. The pump speed pattern 200 can be repeated on a continuous or discontinuous basis, and the increase of rotation speed of the rotor 140 is also sufficiently rapid to produce a desired rate of pressure change.
The concept of overshooting the rotation speed ω2 with a greater speed, such as rotation speed ω1, is based upon partly decoupling pulse pressure, i.e. the difference between the blood pressures before and after the speed change, from the volume flow rate at the higher speed. Thus, target pulse pressures and volume flow rates can be attained at various flow conditions. Ideal values will vary with particular pump design and requirements.
As shown in
Operating the pump at the rotation speed ω2 during the period 210b can contribute to a high hydraulic efficiency during the pump speed pattern 200. During the pump speed pattern 200, the pulse pressure generated in a patient's body is generally correlated to the change in pump rotation speed, for example, the magnitude of the speed change between the speeds ω3 and ω1 at time T4. Therefore, to simulate a pressure change that occurs at the beginning of systole of a physiologic pulse, a significant speed differential between the rotation speeds ω3 and ω1 is generally desired. The speed differential can be, for example, 1000 rpm, 2000 rpm, or more depending on the characteristics of the blood pump 100. Due to the magnitude of the speed differential, one or both of the speeds ω3 to ω1 may occur outside the range of highest operating efficiency of the blood pump 100.
The rotation speed ω2 can be a speed that results in a high hydraulic efficiency of the blood pump 100, for example, a speed near the middle of the operating range of the blood pump 100. During the pump speed pattern 200, the blood pump 100 can operate at the speed ω2 that results in high efficiency for a significant portion of the pump speed pattern 200, contributing to a high efficiency. As described above, the blood pump 100 can operate at the speed ω2 for more than half of the duration at the pump speed pattern 200. Thus the blood pump 100 can operate in a highly efficient manner for the majority of the pump speed pattern 200 and can also produce a pressure change that simulates the beginning of systole of a physiologic heart. Accordingly, some implementations of the pump speed pattern 200 can provide a higher efficiency than control modes that attempt to mimic all aspects of a native cardiac cycle.
The length of the period 210b relative to the length of the pump speed pattern 200 can vary based on the frequency of the artificial pulse. The duration of the period 210a and of the portion 220, by contrast, can be independent of the pulse rate. To produce the desired physiological response, a minimum duration for the period 210a and the portion 220 can be selected, for example, 0.125 seconds. The period 210b can fill the remainder of the pump speed pattern 200.
As an example, the pump speed pattern 200 can have a duration of one second, for a frequency of 60 cycles per minute. Given that the period 210a and the portion 220 have a combined duration of 0.125 seconds, the period 210b can have a duration of 0.750 seconds, or 75% of the pump speed pattern 200. As another example, when the pump speed pattern 200 has a duration of two seconds (and thus a frequency of 30 cycles per minute), the duration of the period 210b can be 1.75 seconds, which is 87.5% of the duration of the pump speed pattern 200.
In some implementations, the rotation speed ω2 is selected such that the operation of the blood pump 100 at the rotation speed ω2 produces a flow rate that has a predetermined relationship relative to the average flow rate during the pump speed pattern 200. The flow rate during the portion 210b can be within a predefined range of the average flow rate, for example, within 30% or within 10% of the average flow rate. The flow rate during the portion 210b can be substantially equal to the average flow rate.
Selecting the rotation speed ω2 to produce a flow rate that is substantially equal to the average flow rate can facilitate a transition between a pulsatile control mode and another control mode, such as a continuous flow control mode. In some implementations, the blood pump 100 operates at a particular constant speed for the greater part of the pump speed pattern 200. Operation at the constant speed can occur during, for example, the period 210b. By adjusting the speeds ω1 and ω3 and duration of the period 210a and of the portion 220, the average pump volume flow rate can be tuned to substantially match an average pump volume flow rate that would be realized in a different optional setting. Consequently, a clinician or patient can switch from an artificial pulse mode to another control mode in a manner that causes only a small difference or no difference in average volume flow rate. This can provide a clinical advantage when the artificial pulse is a selectable option among at least one alternative, for example, a constant speed option.
As an example, a speed set by a clinician for a constant speed mode can also be utilized for a constant speed portion of an artificial pulse mode. The speed can be selected by the clinician to produce a desired volume flow rate through the blood pump 100 during the constant speed mode (e.g., during continuous flow or non-pulsatile operation of the blood pump 100). In the artificial pulse mode, the same selected speed can be used as, for example, the rotation speed ω2 during the period 210b of the pump speed pattern 200. The speeds ω1, ω3 and the duration of the period 210a and the portion 220 are calculated or chosen to approximately balance the volume flow rate for the pump speed pattern 200. For example, the reduced flow rate during the portion 220 can offset the increased flow rate during the portion 210a. As a result, the net volume flow rate during the pump speed pattern 200 can substantially match the volume flow rate during the constant speed mode. Thus in either the constant speed mode or the artificial pulse mode, the volume flow rate can be approximately the same, permitting the clinician to switch from one mode to another without affecting the volume flow rate. This can help avoid potentially dangerous conditions that could occur if switching from one mode to another resulted in sudden changes in flow rate. For example, a sudden decrease in volume flow rate could cause acutely insufficient perfusion for the patient, and a sudden increase in volume flow rate could cause ventricular suction and arrhythmia.
As mentioned above, the second portion 210 of the pump speed pattern 200 can also include multiple segments. For example, as shown in
Similar to the concept of overshooting ω2 in pattern 200, the concept of overshooting the rotation speed ω4 with a lower rotation speed, such as the rotation speed ω3, is also based upon decoupling pulse pressure from the volume flow rate at the lower rotation speed ω4. Thus, the pump speed pattern 300 more completely decouples target pulse pressures and volume flow rates than the pump speed pattern 200, and ideal values can be attained, or more closely approximated, at various flow conditions.
While a single overshoot pump speed for a transition between pump speeds are illustrated and described with reference to
The concept of creating multiple stepwise rotation speed changes is based upon producing the physiologic response that is similar to that produced during human cardiac systole and diastole. This is distinct from mimicking the nature of a native pulse waveform in its entirety. As described above, greater hydraulic efficiency can often be achieved by avoiding imitation of the physiologic pressure waveform over the pulse cycle. It was previously mentioned that an artificial pulse offers a multitude of potential clinical advantages. For some or all of these potential clinical advantages, the benefit of closely matching the energy dissipated during a healthy native pulse varies. To the extent that close matching facilitates achieving these potential clinical advantages, the additional complexity of pattern 400 may be warranted.
In contrast to the stepped or discontinuous transitions discussed above with respect to
The concept of creating multiple speed changes at a strategically-selected rate is based upon producing the physiologic response that is similar to that produced during human cardiac systole and diastole. For example, if very accurate matching of energy dissipation during a human pulse is necessary, the additional complexity of pattern 500 may be warranted.
The pump speed pattern 500 illustrates the difference between stepped transitions discussed above with respect to pump speed patterns 200-400, produced by rapidly changing the rotation speed of the rotor 140, and the gradual transitions of the first segment 510a of the first portion 510 and the first segment 520a of the second portion 520 of the pump speed pattern 500. Such gradual transitions can be included, for example, to mimic pressure changes exhibited during native diastole, as may be achieved by the gradual transition of the first segment 510a of the first portion 510 of the pump speed pattern 500. In some implementations, one or more of the rotation speed decreases of a pump speed pattern can be gradual transitions. For example, a pump speed pattern can include a gradual decrease in rotation speed from the first rotation speed ω1 to the third rotation speed ω3 and a stepped transition from the third pump speed ω3 back to the first rotation speed ω1. Various combinations of stepped and gradual transitions can be included in a pump speed pattern to produce a desired arterial pressure wave form, or other desired physiologic effect. Additionally, the type of transition between rotation speeds can affect power consumption of the blood pump 100, and the pump speed pattern can be selected based, at least in part, on power consumption considerations.
For all the pump speed patterns discussed it should be appreciated that although rotor speed is the technological parameter utilized to impart an artificial pulse, any physiologic effect is related to the consequential pressure and flow patterns, including pulse pressure, the maximum time variation in rate of blood pressure change (dp/dt), and the like. Rotor speed is not intrinsically physiologically meaningful. The human vascular system naturally dampens the native pulse produced by the heart, and it will do the same for an artificial pulse produced as described. The invention describes a utilitarian combination of factors that result in a physiological meaningful pulse. Thus, the pump speed patterns 200-500 described above are exemplary combinations of parameters that result in a physiologically meaningful pulse.
In use, the pump speed patterns 200-500 can be generated by a controller that is configured to generate an electrical drive signal to operate the blood pump 100. For example, the controller can include a computer system 600, shown in
The computer system 600 includes one or more processors 610, memory modules 620, storage devices 630, and input/output devices 640 connected by a system bus 650. The input/output devices 640 are operable to communicate signals to, and/or receive signals from, one or more peripheral devices 660. For example, a peripheral device 660 can be used to store computer executable instructions on the memory modules 620 and/or the storage devices 630 that are operable, when executed by the processors, to cause the controller to generate a waveform to control the operation of the pump 100 and produce a pump speed pattern, such as the pump speed patterns 200-500.
Additionally, the controller can include a sensor that provides a signal that indicates activity of the heart H. For example, the controller can include a sensor that provides a signal indicative of power consumption of the blood pump 100. The signal can be used to determine when the left ventricle LV contracts. For example, the power consumption of the blood pump 100 may, for a given operating speed, increase as the left ventricle LV contracts. Based on the determined heart activity, the controller can adjust the generated control waveform. For example, the controller can automatically adjust the timing and duration of the first portion 210 and the second portion 220 of the pump speed pattern 200 such that the first portion 210 approximately coincides with a contraction of the left ventricle LV. The pump 100 is controlled such that the time T0 approximately coincides with a beginning of a contraction of the left ventricle LV and the time T2 approximately coincides with an end of the contraction of the left ventricle LV. The time T4 approximately coincides with a beginning of a subsequent contraction of the left ventricle LV. Thus, the durations of the various portions and/or segments of the pump speed patterns described above can be changed individually or collectively for one or more repetitions of the pump speed patterns. Using these techniques, the controller can synchronize the pulsatile operation of the blood pump 100 with the natural physiologic pulse of the heart H.
Alternatively, the controller can generate the control waveform independently of the activity of the heart H and/or to operate in opposition to the activity of the heart H, such as where the first portion 210 occurs during left ventricular relaxation. Similarly, the controller can generate a control waveform that includes a distinctly non-physiologic pulse rate, such as fewer than 40 high-pressure periods per minute, and the waveform can be generated independently of native heart function. In some examples, the blood pump 100 can be operated to produce distinctly physiologic pulse rates, such as between 50 and 110 high-pressure periods per minute, and can be controlled dependently or independently of heart function.
A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the claimed invention. For example, the pump speed patterns described above can be used with various types of blood pumps, including axial flow blood pumps and centrifugal flow blood pumps. Similarly, the rotors of blood pumps used to produce pulsatile blood flow patterns as described above may be electromagnetically-suspended, hydraulically-suspended, mechanically-suspended, or combinations thereof. The rotors may also partially be passively magnetically-suspended. However, the effect of an artificial pulse may most accurately be simulated by a pump in which the rotor is electromagnetically suspended, with or without partial passive magnetic suspension, because in general, other things being equal, electromagnetic suspension yields a high degree of responsiveness of the rotor to speed change inputs. For example, mechanical bearings associated with mechanical suspension and/or very narrow rotor clearance gaps associated with hydraulic suspension hinder rapid acceleration of the rotor compared to similar pumps that employ electromagnetic suspension. Additionally, while the pump speed patterns described above have been described with regard to a measure of angular velocity, the pump speed patterns can be produced with regard to one or more different measures of pump speeds. Additionally, there may be a delay between a change in drive signal generated by the controller and a change in operating speed of the blood pump. Thus, the controller can be operated such that changes in the output drive signal are effected at a time to produce a corresponding change in pump operating speed at a desired time, such as a time that approximately coincides with selected activity of the heart.
In some implementations, the pump speed patterns 200-500 can include additional portions or segments during which the blood pump is operated at other speeds. For example, at desired times, the blood pump can be operated to produce a pump speed pattern that produces a desired physiologic effect, such as opening or closing the aortic valve. Such operation of the blood pump can interrupt a generally continuous repetition of a selected one or more of the pump speed patterns described above, or others, including an indefinite period of constant speed, and a selected pump speed pattern can be resumed after the desired physiologic effect has been produced. The pump speed patterns 200-500 can also include different portions or segments. For example, the second segment 210b of the first portion 210 of the pump speed pattern 200 can include multiple pump speeds. Similarly, the transitions between pump speeds, such as the reduction in pump speed from the first rotation speed ω1 to the second rotation speed ω2, can include constant, variable, exponential, combinations thereof, or other rate of speed change over time such that the transition, such as the first segment 510a of the first portion 510 of the pump speed pattern 500, is linear, curvilinear, parabolic, logarithmic, sinusoidal, stepped, or combinations thereof.
In some implementations, one or more of the pump speed changes in the pump speed patterns 200-500 can be monotonic. A transition from one speed to another may occur gradually over a period of time, yet change directly from one speed to another. For example, to decrease a pump speed from a first rotational speed to a second rotational speed, the controller can reduce the pump speed without causing an intervening period of increasing pump speed. Similarly, the transition from the first rotational speed to the second rotational speed can occur without operating the pump above the first rotational speed during the transition.
Additionally, a blood pump can be operated according to a pump speed pattern that is selected according to a pump power consumption rate associated with the pump speed pattern, a pump efficiency associated with the pump speed pattern, a blood flow rate associated with the pump speed pattern, and/or a rate of blood pressure change associated with the pump speed pattern. For example, in a first mode, the controller can be operated to produce a pump speed pattern that produces a desired rate of blood pressure change. When a low power condition is detected, the controller can be switched to a power-saving mode to produce a pump speed pattern that has a low power consumption rate, even if the desired rate of pressure change is not produced in the power-saving mode.
As mentioned above, in some implementations, the blood pump 100 can be used to assist a patient's heart during a transition period, such as during a recovery from illness and/or surgery or other treatment. In other implementations, the blood pump 100 can be used to partially or completely replace the function of the patient's heart on a generally permanent basis, such as where the patient's aortic valve is surgically sealed.
The subject matter and the functional operations described in this specification can be implemented in digital electronic circuitry, in tangibly-embodied computer software or firmware, in computer hardware, including the structures disclosed in this specification and their structural equivalents, or in combinations of one or more of them. The subject matter described in this specification can be implemented as one or more computer programs, i.e., one or more modules of computer program instructions encoded on a tangible non transitory program carrier for execution by, or to control the operation of, data processing apparatus. The program carrier can be a computer storage medium, for example, a machine-readable storage device, a machine-readable storage substrate, a random or serial access memory device, or a combination of one or more of them, as described further below. Alternatively or in addition, the program instructions can be encoded on an artificially generated propagated signal, e.g., a machine-generated electrical, optical, or electromagnetic signal, that is generated to encode information for transmission to suitable receiver apparatus for execution by a data processing apparatus.
The term “data processing apparatus” encompasses all kinds of apparatus, devices, and machines for processing data, including by way of example a programmable processor, a computer, or multiple processors or computers. The apparatus can include special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application specific integrated circuit). The apparatus can also include, in addition to hardware, code that creates an execution environment for the computer program in question, e.g., code that constitutes processor firmware, a protocol stack, a database management system, an operating system, or a combination of one or more of them.
A computer program (which may also be referred to or described as a program, software, a software application, a module, a software module, a script, or code) can be written in any form of programming language, including compiled or interpreted languages, or declarative or procedural languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. A computer program may, but need not, correspond to a file in a file system. A program can be stored in a portion of a file that holds other programs or data, e.g., one or more scripts stored in a markup language document, in a single file dedicated to the program in question, or in multiple coordinated files, e.g., files that store one or more modules, sub programs, or portions of code. A computer program can be deployed to be executed on one computer or on multiple computers that are located at one site or distributed across multiple sites and interconnected by a communication network.
The processes and logic flows described in this specification can be performed by one or more programmable computers executing one or more computer programs to perform functions by operating on input data and generating output. The processes and logic flows can also be performed by, and apparatus can also be implemented as, special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application specific integrated circuit).
Computers suitable for the execution of a computer program can include, by way of example, general or special purpose microprocessors or both, or any other kind of central processing unit. Generally, a central processing unit will receive instructions and data from a read only memory or a random access memory or both. The essential elements of a computer are a processing unit for performing or executing instructions and one or more memory devices for storing instructions and data. A computer can also include, or be operatively coupled to receive data from or transfer data to, or both, one or more mass storage devices for storing data, e.g., magnetic, magneto optical disks, or optical disks. However, a computer need not have such devices. Moreover, a computer can be embedded in another device, e.g., a pump, a pump controller, or a portable storage device, e.g., a universal serial bus (USB) flash drive or other removable storage module, to name a few.
Computer readable media suitable for storing computer program instructions and data include all forms of non-volatile memory, media and memory devices, including by way of example semiconductor memory devices, e.g., EPROM, EEPROM, and flash memory devices; magnetic disks, e.g., internal hard disks or removable disks; magneto optical disks; and CD ROM and DVD-ROM disks. The processor and the memory can be supplemented by, or incorporated in, special purpose logic circuitry.
Accordingly, other embodiments are within the scope of the following claims.
The present application is a Continuation of U.S. application Ser. No. 16/055,471 filed Aug. 6, 2018 (Allowed); which is a Continuation of U.S. application Ser. No. 15/785,097 filed Oct. 16, 2017 (now U.S. Pat. No. 10,086,122); which is a Continuation of U.S. patent application Ser. No. 15/221,456 filed Jul. 27, 2016 (now U.S. Pat. No. 9,801,988); which is a Continuation of U.S. patent application Ser. No. 14/592,630 filed Jan. 8, 2015 (now U.S. Pat. No. 9,433,717); which is a Continuation of U.S. patent application Ser. No. 14/261,817 filed Apr. 25, 2014 (now U.S. Pat. No. 8,961,388); which is a Continuation of U.S. application Ser. No. 13/926,044 filed Jun. 25, 2013 (now U.S. Pat. No. 9,011,312); which is a Divisional of U.S. patent application Ser. No. 13/241,831 filed Sep. 23, 2011 (now U.S. Pat. No. 8,506,471); which claims the benefit of U.S. Provisional Appln No. 61/386,018 filed Sep. 24, 2010; the disclosures of which are incorporated herein by reference in their entirety for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3240207 | Barker et al. | Mar 1966 | A |
| 3911897 | Leachman | Oct 1975 | A |
| 4190057 | Hill et al. | Feb 1980 | A |
| 4296500 | Monties et al. | Oct 1981 | A |
| 4600855 | Strachan | Jul 1986 | A |
| 4957504 | Chardack | Sep 1990 | A |
| 5139517 | Corral | Aug 1992 | A |
| 5279292 | Baumann et al. | Jan 1994 | A |
| 5289821 | Swartz | Mar 1994 | A |
| 5290227 | Pasque | Mar 1994 | A |
| 5318592 | Schaldach | Jun 1994 | A |
| 5385581 | Bramm et al. | Jan 1995 | A |
| 5503615 | Goldstein | Apr 1996 | A |
| 5658318 | Stroetmann et al. | Aug 1997 | A |
| 5693091 | Larson et al. | Dec 1997 | A |
| 5715837 | Chen | Feb 1998 | A |
| 5725357 | Nakazeki et al. | Mar 1998 | A |
| 5798454 | Nakazeki et al. | Aug 1998 | A |
| 5807258 | Cimochowski et al. | Sep 1998 | A |
| 5888242 | Antaki et al. | Mar 1999 | A |
| 5947703 | Nojiri et al. | Sep 1999 | A |
| 6027498 | Mutch et al. | Feb 2000 | A |
| 6048363 | Nagyszalanczy et al. | Apr 2000 | A |
| 6053873 | Govari et al. | Apr 2000 | A |
| 6066086 | Antaki et al. | May 2000 | A |
| 6139487 | Siess | Oct 2000 | A |
| 6142752 | Akamatsu et al. | Nov 2000 | A |
| 6146325 | Lewis et al. | Nov 2000 | A |
| 6171253 | Bullister et al. | Jan 2001 | B1 |
| 6176822 | Nix et al. | Jan 2001 | B1 |
| 6264601 | Jassawalla et al. | Jul 2001 | B1 |
| 6264635 | Wampler et al. | Jul 2001 | B1 |
| 6277078 | Porat et al. | Aug 2001 | B1 |
| 6293901 | Prem | Sep 2001 | B1 |
| 6367333 | Bullister et al. | Apr 2002 | B1 |
| 6395027 | Snyder | May 2002 | B1 |
| 6409674 | Brockway et al. | Jun 2002 | B1 |
| 6422990 | Prem | Jul 2002 | B1 |
| 6443884 | Miyawaki | Sep 2002 | B1 |
| 6468041 | Ozaki | Oct 2002 | B2 |
| 6481292 | Reich | Nov 2002 | B1 |
| 6540658 | Fasciano et al. | Apr 2003 | B1 |
| 6547753 | Plunkett et al. | Apr 2003 | B1 |
| 6575717 | Ozaki et al. | Jun 2003 | B2 |
| 6585635 | Aldrich | Jul 2003 | B1 |
| 6589030 | Ozaki | Jul 2003 | B2 |
| 6605032 | Benkowski et al. | Aug 2003 | B2 |
| 6623420 | Reich et al. | Sep 2003 | B2 |
| 6626644 | Ozaki | Sep 2003 | B2 |
| 6636769 | Govari et al. | Oct 2003 | B2 |
| 6669624 | Frazier | Dec 2003 | B2 |
| 6688861 | Wampler | Feb 2004 | B2 |
| 6707200 | Carroll et al. | Mar 2004 | B2 |
| 6716189 | Jarvik et al. | Apr 2004 | B1 |
| 6736980 | Moscaritolo | May 2004 | B2 |
| 6742999 | Nüsser et al. | Jun 2004 | B1 |
| 6817836 | Nose et al. | Nov 2004 | B2 |
| 6890303 | Fitz | May 2005 | B2 |
| 6949066 | Bearnson et al. | Sep 2005 | B2 |
| 6969345 | Jassawalla et al. | Nov 2005 | B2 |
| 6974436 | Aboul-Hosn et al. | Dec 2005 | B1 |
| 6984201 | Khaghani et al. | Jan 2006 | B2 |
| 6991595 | Burke et al. | Jan 2006 | B2 |
| 7029433 | Chang | Apr 2006 | B2 |
| 7138776 | Gauthier et al. | Nov 2006 | B1 |
| 7147604 | Allen et al. | Dec 2006 | B1 |
| 7150711 | Nusser et al. | Dec 2006 | B2 |
| 7160242 | Yanai | Jan 2007 | B2 |
| 7175588 | Morello | Feb 2007 | B2 |
| 7211048 | Najafi et al. | May 2007 | B1 |
| 7229474 | Hoffmann et al. | Jun 2007 | B2 |
| 7239098 | Masino | Jul 2007 | B2 |
| 7284956 | Nose et al. | Oct 2007 | B2 |
| 7320706 | Al-Najjar | Jan 2008 | B2 |
| 7396327 | Morello | Jul 2008 | B2 |
| 7462019 | Allarie et al. | Dec 2008 | B1 |
| 7497116 | Miyakoshi et al. | Mar 2009 | B2 |
| 7511443 | Townsend et al. | Mar 2009 | B2 |
| 7520850 | Brockway | Apr 2009 | B2 |
| 7578782 | Miles et al. | Aug 2009 | B2 |
| 7591777 | LaRose | Sep 2009 | B2 |
| 7645225 | Medvedev et al. | Jan 2010 | B2 |
| 7645255 | Gordon et al. | Jan 2010 | B2 |
| 7699588 | Mendler | Apr 2010 | B2 |
| 7850594 | Sutton et al. | Dec 2010 | B2 |
| 7854631 | Townsendl et al. | Dec 2010 | B2 |
| 7861582 | Miyakoshi et al. | Jan 2011 | B2 |
| 7887479 | LaRose et al. | Feb 2011 | B2 |
| 7951062 | Morello | May 2011 | B2 |
| 7963905 | Salmonsen et al. | Jun 2011 | B2 |
| 7976271 | LaRose et al. | Jul 2011 | B2 |
| 7988728 | Ayre | Aug 2011 | B2 |
| 7998054 | Bolling | Aug 2011 | B2 |
| 8043074 | Tada | Oct 2011 | B2 |
| 8123669 | Siess et al. | Feb 2012 | B2 |
| 8157720 | Marseille et al. | Apr 2012 | B2 |
| 8246530 | Sullivan | Aug 2012 | B2 |
| 8303482 | Schima et al. | Nov 2012 | B2 |
| 8382830 | Maher et al. | Feb 2013 | B2 |
| 8506470 | LaRose et al. | Aug 2013 | B2 |
| 8506471 | Bourque | Aug 2013 | B2 |
| 8517699 | Horvath | Aug 2013 | B2 |
| 8556795 | Bolyard et al. | Oct 2013 | B2 |
| 8597350 | Rudser et al. | Dec 2013 | B2 |
| 8657733 | Ayre et al. | Feb 2014 | B2 |
| 8657875 | Kung et al. | Feb 2014 | B2 |
| 8764621 | Badstibner et al. | Jul 2014 | B2 |
| 8771165 | Choi et al. | Jul 2014 | B2 |
| 8852099 | Von Arx et al. | Oct 2014 | B2 |
| 8870739 | LaRose et al. | Oct 2014 | B2 |
| 8882477 | Fritz, IV et al. | Nov 2014 | B2 |
| 8956275 | Bolyard et al. | Feb 2015 | B2 |
| 9387284 | Heilman et al. | Jul 2016 | B2 |
| 9433714 | Voskoboynikov et al. | Sep 2016 | B2 |
| 9433717 | Bourque | Sep 2016 | B2 |
| 9801988 | Bourque | Oct 2017 | B2 |
| 20020116055 | Snyder | Aug 2002 | A1 |
| 20020183628 | Reich et al. | Dec 2002 | A1 |
| 20030023255 | Miles et al. | Jan 2003 | A1 |
| 20030045772 | Reich et al. | Mar 2003 | A1 |
| 20030074144 | Freed et al. | Apr 2003 | A1 |
| 20030199727 | Burke et al. | Oct 2003 | A1 |
| 20040034272 | Diaz et al. | Feb 2004 | A1 |
| 20040064012 | Yanai | Apr 2004 | A1 |
| 20050071001 | Jarvik | Mar 2005 | A1 |
| 20050107658 | Brockway | May 2005 | A1 |
| 20050131271 | Benkowski et al. | Jun 2005 | A1 |
| 20050159639 | Skliar et al. | Jul 2005 | A1 |
| 20060047205 | Ludomirsky et al. | Mar 2006 | A1 |
| 20060155158 | Aboul-Hosn | Jul 2006 | A1 |
| 20060229488 | Ayre et al. | Oct 2006 | A1 |
| 20060241335 | Benkowski et al. | Oct 2006 | A1 |
| 20070073393 | Kung et al. | Mar 2007 | A1 |
| 20070083077 | Frazier | Apr 2007 | A1 |
| 20070142923 | Ayre et al. | Jun 2007 | A1 |
| 20070282210 | Stern | Dec 2007 | A1 |
| 20080154095 | Stubkjaer et al. | Jun 2008 | A1 |
| 20080281146 | Morello | Nov 2008 | A1 |
| 20080319544 | Yaegashi | Dec 2008 | A1 |
| 20090099406 | Salmonsen et al. | Apr 2009 | A1 |
| 20090138080 | Siess et al. | May 2009 | A1 |
| 20090156885 | Morello et al. | Jun 2009 | A1 |
| 20100130809 | Morello | May 2010 | A1 |
| 20100152526 | Pacella et al. | Jun 2010 | A1 |
| 20100222632 | Poirier | Sep 2010 | A1 |
| 20100222633 | Poirier | Sep 2010 | A1 |
| 20100222634 | Poirier | Sep 2010 | A1 |
| 20100222635 | Poirier | Sep 2010 | A1 |
| 20100222878 | Poirier | Sep 2010 | A1 |
| 20100241223 | Lee et al. | Sep 2010 | A1 |
| 20100327687 | Iannello et al. | Dec 2010 | A1 |
| 20110054239 | Sutton et al. | Mar 2011 | A1 |
| 20110071337 | Thompson et al. | Mar 2011 | A1 |
| 20110112354 | Nishimura et al. | May 2011 | A1 |
| 20110237863 | Ricci et al. | Sep 2011 | A1 |
| 20110313237 | Miyakoshi et al. | Dec 2011 | A1 |
| 20120078030 | Bourque | Mar 2012 | A1 |
| 20120078031 | Burke et al. | Mar 2012 | A1 |
| 20120226097 | Smith et al. | Sep 2012 | A1 |
| 20120245681 | Casas et al. | Sep 2012 | A1 |
| 20130331934 | Kabir et al. | Dec 2013 | A1 |
| 20140012067 | Poirier | Jan 2014 | A1 |
| 20140058190 | Gohean et al. | Feb 2014 | A1 |
| 20140100413 | Casas et al. | Apr 2014 | A1 |
| 20140194985 | Vadala, Jr. | Jul 2014 | A1 |
| 20140235931 | Bourque | Aug 2014 | A1 |
| 20140275723 | Fritz, IV et al. | Sep 2014 | A1 |
| 20140275727 | Bonde et al. | Sep 2014 | A1 |
| 20140303426 | Kerkhoffs et al. | Oct 2014 | A1 |
| 20140357937 | Reyes et al. | Dec 2014 | A1 |
| 20150051438 | Taskin | Feb 2015 | A1 |
| 20150057488 | Yomtov | Feb 2015 | A1 |
| 20150151032 | Voskoboynikov et al. | Jun 2015 | A1 |
| 20150174307 | Eckman et al. | Jun 2015 | A1 |
| 20150328466 | Peters et al. | Nov 2015 | A1 |
| 20160058929 | Medvedev et al. | Mar 2016 | A1 |
| 20160058930 | Medvedev et al. | Mar 2016 | A1 |
| 20160101230 | Ochsner et al. | Apr 2016 | A1 |
| 20160193397 | Aber et al. | Jul 2016 | A9 |
| 20160263299 | Xu et al. | Sep 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 445782 | Aug 1994 | EP |
| 499939 | Aug 1994 | EP |
| 1046403 | Oct 2000 | EP |
| 1354606 | Oct 2003 | EP |
| 2298375 | Mar 2011 | EP |
| 2618862 | Jul 2013 | EP |
| 2618863 | Jul 2013 | EP |
| 2152241 | Jul 1985 | GB |
| 58054929 | Apr 1983 | JP |
| 04504673 | Aug 1992 | JP |
| 09276397 | Oct 1997 | JP |
| 2002224066 | Aug 2002 | JP |
| 2003501180 | Jan 2003 | JP |
| 2004510482 | Apr 2004 | JP |
| 2005514962 | May 2005 | JP |
| 2008543378 | Dec 2008 | JP |
| 2009-297174 | Dec 2009 | JP |
| 2009297174 | Dec 2009 | JP |
| 2013540005 | Oct 2013 | JP |
| 2013540006 | Oct 2013 | JP |
| 2013240006 | Nov 2013 | JP |
| 201221160 | Jun 2012 | TW |
| 9215239 | Sep 1992 | WO |
| 9959652 | Nov 1999 | WO |
| 0069490 | Nov 2000 | WO |
| 0076288 | Dec 2000 | WO |
| 0076822 | Dec 2000 | WO |
| 0112070 | Feb 2001 | WO |
| 0172352 | Oct 2001 | WO |
| 03015609 | Feb 2003 | WO |
| 2004028593 | Apr 2004 | WO |
| 2005006975 | Jan 2005 | WO |
| 2005051838 | Jun 2005 | WO |
| 2006133409 | Dec 2006 | WO |
| 2009150893 | Dec 2009 | WO |
| 2010025411 | Mar 2010 | WO |
| 2010099411 | Sep 2010 | WO |
| 2012040544 | Mar 2012 | WO |
| Entry |
|---|
| English Translation (machine) of JP 2009-297174 (Year: 2009). |
| Bullister et al., “Physiologic Control Algorithms for Rotary Blood Pumps using Pressure Sensor Input”, Organs, vol. 26, No. 11, 2002, pp. 931-938. |
| Ednick et al., “Telemetric Recording of Intrapleural Pressure”, Journal of Surgical Research, vol. 138, No. 1, 2007, pp. 10-14. |
| Ellozy et al., “First Experience in Human Beings with a Permanently Implantable Intrasac Pressure Transducer for Monitoring Endovascular Repair of Abdominal Aortic Aneurysms”, J Vase Surg., vol. 40, Sep. 2004, pp. 405-412. |
| Ferreira et al., “A Rule-Based Controller Based on Suction Detection for Rotary Blood Pumps”, Conf Proc IEEE Eng Med Bioi Soc., 2007, pp. 3978-3981. |
| Fukamachi et al., “An Innovative, Sensorless, Pulsatile, Continuous-Flow Total Artificial Heart: Device Design and Initial In Vitro Study”, The Journal of Heart and Lung Transplantation, vol. 29, No. 1, Jan. 2010, 20 pages. |
| Giridharan et al., “Control Strategy for Maintaining Physiological Perfusion with Rotary Blood Pumps”, Artif Organs, vol. 27, No. 7, 2003, pp. 639-648. |
| Haj-Yahia , “Midterm Experience with the Jarvik 2000 Axial Flow Left Ventricular Assist Device”, J Thorac Cardiovasc Surg., vol. 134, No. 1, 2007, pp. 199-203. |
| Ising et al., “Flow Modulation Algorithms for Continuous Flow Left Ventricular Assist Devices to Increase Vascular Pulsatility: A Computer Simulation Study”, Cardiovascular Engineering and Technology, vol. 2, No. 2, Mar. 26, 2011, pp. 90-100. |
| Khalil et al., “Induced Pulsation of a Continuous-Flow Total Artificial Heart in a Mock Circulatory System”, The Journal of Heart and Lung Transplantation, vol. 29, No. 5, May 2010, pp. 568-573. |
| Letsou et al., “Is Native Aortic Valve Commissural Fusion in Patients with Long-Term Left Ventricular Assist Devices Associated with Clinically Important Aortic Insufficiency”, The Journal of Heart and Lung Transplantation, vol. 25, No. 4, Apr. 2006, pp. 395-399. |
| Ohuchi et al., “Control Strategy for Rotary Blood Pumps”, Artif Organs, vol. 25, No. 5, May 2001, pp. 366-370. |
| Reesink et al., “Suction Due to Left Ventricular Assist: Implications for Device Control and Management”, Artif Organs, vol. 31, No. 7, 2007, pp. 542-549. |
| Rozenman , “Wireless Acoustic Communication with a Miniature Pressure Sensor in the Pulmonary Artery for Disease Surveillance and Therapy of Patients with Congestive Heart Failure”, Journal of the American College of Cardiology, vol. 49, No. 7, Feb. 20, 2007, pp. 784-789. |
| Shi et al., “Numerical Modeling of Hemodynamics with Pulsatile Impeller Pump Support”, Annals of Biomedical Engineering, vol. 38, No. 8, Aug. 2010, pp. 2621-2634. |
| Shi et al., “Numerical Simulation of Cardiovascular Dynamics with Left Heart Failure and In-Series Pulsatile Ventricular Assist Device”, Artificial Organs, vol. 30, No. 12, 2006, pp. 929-948. |
| Shiose et al., “Speed Modulation of the Continuous-Flow Total Artificial Heart to Simulate a Physiologic Arterial Pressure Waveform”, ASAIO Journal, vol. 56, No. 5, 2010, pp. 403-409. |
| Travis et al., “Vascular Pulsatility in Patients with a Pulsatile- or Continuous-Flow Ventricular Assist Device”, Journal of Thoracis and Cardiovascular Surgery, vol. 133, No. 2, Feb. 2007, pp. 517-524. |
| Tuzun et al., “The Effect of Intermittent Low Speed Mode upon Aortic Valve Opening in Calves Supported with a Jarvik 2000 Axial Flow Device.”, ASAIO Journal, vol. 51, No. 2, 2005, pp. 139-143. |
| Vandenberghe et al., “Hemodynamic Modes of Ventricular Assist with a Rotary Blood Pump: Continuous, Pulsatile, and Failure”, ASAIO Journal, vol. 51, No. 6, 2005, pp. 711-718. |
| Voigt et al., “Suction Detection for the Micromed Debakey Left Ventricular Assist Device”, ASAIO Journal, vol. 51, No. 4, 2005, pp. 321-328. |
| Vollkron et al., “Development of a Reliable Automatic Speed Control System for Rotary Blood Pumps”, The Journal of Heart and Lung Transplantation, vol. 24, No. 11, Nov. 2005, pp. 1878-1885. |
| Vollkron et al., “Development of a Suction Detection System for Axial Blood Pumps”, Artif Organs, vol. 28, No. 8, 2004, pp. 709-716. |
| Number | Date | Country | |
|---|---|---|---|
| 20210077688 A1 | Mar 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61386018 | Sep 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13241831 | Sep 2011 | US |
| Child | 13926044 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16055471 | Aug 2018 | US |
| Child | 17103283 | US | |
| Parent | 15785097 | Oct 2017 | US |
| Child | 16055471 | US | |
| Parent | 15221456 | Jul 2016 | US |
| Child | 15785097 | US | |
| Parent | 14592630 | Jan 2015 | US |
| Child | 15221456 | US | |
| Parent | 14261817 | Apr 2014 | US |
| Child | 14592630 | US | |
| Parent | 13926044 | Jun 2013 | US |
| Child | 14261817 | US |
